OTC: HLUBF - H. Lundbeck A/S

Altı ay boyunca karlılık: -27.38%
Temettü getirisi: +16.83%
Sektör: Healthcare

Promosyon programı H. Lundbeck A/S


Şirket hakkında H. Lundbeck A/S

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia.

daha fazla ayrıntı
It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with FeetMe focusing on the use of sensor shoe soles. H. Lundbeck A/S also has a collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.

Industry Pharmaceuticals
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 16.83
Дивиденд ао 0.7
Сайт https://www.lundbeck.com
Цена ао 4.43
Günlük fiyat değişimi: 0% (4.43)
Haftalık fiyat değişimi: 0% (4.43)
Aylık fiyat değişimi: 0% (4.43)
3 ayda fiyat değişimi: -15.09% (5.2175)
Altı ayda fiyat değişimi: -27.38% (6.1)
Yıllık fiyat değişimi: +3.87% (4.265)
3 yılda fiyat değişimi: 0% (4.43)
5 yılda fiyat değişimi: 0% (4.43)
10 yılda fiyat değişimi: 0% (4.43)
Yılbaşından bu yana fiyat değişimi: -15.62% (5.25)

Hafife alma

İsim Anlam Seviye
P/S 1.39 9
P/BV 0.1858 10
P/E 12.08 8
EV/EBITDA 4.3 10
Toplam: 9.38

Yeterlik

İsim Anlam Seviye
ROA, % 0.9065 1
ROE, % 1.54 1
Toplam: 2.5

Temettüler

İsim Anlam Seviye
Div yield, % 16.83 10
DSI 1 10
Toplam: 8.41

Görev

İsim Anlam Seviye
Debt/EBITDA 5.05 0
Toplam: 6

Büyüme dürtüsü

İsim Anlam Seviye
karlılık Revenue, % -83.42 0
karlılık Ebitda, % -81.03 0
karlılık EPS, % -97.51 0
Toplam: 1.6



Süpervizör İş unvanı Ödeme Doğum yılı
Mr. Joerg Hornstein CFO & Executive VP of Corporate Functions 1.23M 1977 (48 yıllar)
Mr. Lars Bang Executive Vice President of Product Development & Supply 1.14M 1962 (63 yıl)
Dr. Per Johan Luthman Executive Vice President of Research & Development 1.27M 1959 (66 yıllar)
Mr. Charl van Zyl President & CEO 5.34M 1967 (58 yıllar)
Dr. Tarek Samad Ph.D. Senior VP & Head of Research N/A
Mr. Palle Holm Olesen Chief Specialist & VP of Investor Relations N/A
Mr. Ole Chrintz Senior Vice President of International Markets N/A 1958 (67 yıllar)
Dr. Rupert Sandbrink M.D., Ph.D. Senior VP & Head of Clinical Development N/A 1964 (61 yıl)
Ms. Tine Ostergaard Hansen Senior Vice President of Corporate Communications & Public Affairs N/A 1975 (50 yıllar)
Ms. Dianne Holto Executive Vice President of People & Culture 1973 (52 yıl)

Adres: Denmark, Valby, Ottiliavej 9 - Google haritalarda aç, Yandex haritalarını aç
Web sitesi: https://www.lundbeck.com